ValiRx   Report issue

For profit Phase 2
Founded: London United Kingdom (2000)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2014
NCT02280317
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

ValiRx Plc

Active Ingredients

Drugs in Phase 2 Trials (2)

risperidone (risperdal) (1 trial)

val201 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2